Literature DB >> 17631678

Learning curve of combined modality treatment in peritoneal surface disease.

R M Smeenk1, V J Verwaal, F A N Zoetmulder.   

Abstract

BACKGROUND: Cytoreductive surgery with intraperitoneal chemotherapy has emerged as a new standard approach for peritoneal surface disease. This study investigated the learning curve of this combined modality treatment at a single institute.
METHODS: Variables analysed over three consecutive treatment periods (1996-1998, 1999-2002 and 2003-2006) included number of abdominal regions affected, Simplified Peritoneal Cancer Index (SPCI) score, result of cytoreduction, morbidity, duration of hospital stay and survival.
RESULTS: A total of 323 procedures were performed between January 1996 and June 2006, 184 for peritoneal carcinomatosis of colorectal cancer origin and 139 for pseudomyxoma peritonei (PMP), including second procedures in 11 patients with PMP. The mean SPCI score decreased significantly over the study period (P < 0.001), but the number of regions affected did not. The rate of complete cytoreductions increased from 35.6 to 65.1 per cent (P = 0.012). The postoperative morbidity rate decreased from 71.2 to 34.1 per cent (P < 0.001). The median duration of hospital stay decreased from 24 to 17 days. The peak of the learning curve, graded by the percentage of complete cytoreductions, was reached after approximately 130 procedures.
CONCLUSION: The learning curve of combined modality treatment for peritoneal surface disease is long, and reflects patient selection and treatment expertise. Copyright (c) 2007 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17631678     DOI: 10.1002/bjs.5863

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  60 in total

1.  Pseudomyxoma peritonei.

Authors:  Katharine E Bevan; Faheez Mohamed; Brendan J Moran
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

Review 2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Peritonectomy HIPEC-contemporary results, indications.

Authors:  David L Morris
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

Review 4.  Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer.

Authors:  Beate Rau; Andreas Brandl; Andreas Pascher; Wieland Raue; Paul Sugarbaker
Journal:  Visc Med       Date:  2017-02-10

Review 5.  Management of peritoneal carcinomatosis from colorectal cancer.

Authors:  Chukwuemeka U Ihemelandu; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

6.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.

Authors:  Ayman Zaki Azzam; Zyad Adil Alyahya; Ahmed Abbas Al Wusaibie; Tarek Mahmoud Amin
Journal:  Indian J Gastroenterol       Date:  2017-11-29

7.  Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Mariangela Desantis; Jean-Louis Bernard; Vincent Casanova; Marianne Cegarra-Escolano; Emmanuel Benizri; Amine M Rahili; Daniel Benchimol; Jean-Marc Bereder
Journal:  Langenbecks Arch Surg       Date:  2014-10-16       Impact factor: 3.445

Review 8.  Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.

Authors:  Terence C Chua; Tristan D Yan; David L Morris
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

9.  Rare diaphragmatic complications following cytoreductive surgery and HIPEC: report of two cases.

Authors:  Benedikt Lampl; Hubert Leebmann; Max Mayr; Pompiliu Piso
Journal:  Surg Today       Date:  2012-12-07       Impact factor: 2.549

10.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.

Authors:  Parissa Tabrizian; Brian Shrager; Ghalib Jibara; Ming-Jim Yang; Anya Romanoff; Spiros Hiotis; Umut Sarpel; Daniel M Labow
Journal:  J Gastrointest Surg       Date:  2014-02-28       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.